Interaction of fucoidan with the proteins of the complement classical pathway

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1651, Issue 1-2, 2003, Pages 5-16

  Tissot, Bérangère ^a   Montdargent, Béatrice ^a   Chevolot, Lionel ^a   Varenne, Anne ^b   Descroix, Stéphanie ^b   Gareil, Pierre ^b   Daniel, Régis ^a  

^a UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^b PSL RESEARCH UNIVERSITY   (France)

Author keywords

Capillary electrophoresis; Carbohydrate protein interaction; Complement system; Fucoidan; Inhibitor

Indexed keywords

ALGAL PROTEIN; CARBOHYDRATE BINDING PROTEIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT INHIBITOR; FUCOIDIN; LYSINE; ANTIINFLAMMATORY AGENT; COMPLEMENT COMPONENT C4; MULTIENZYME COMPLEX; POLYSACCHARIDE; SULFATE;

AFFINITY CAPILLARY ELECTROPHORESIS; ALGA; ARTICLE; ASCOPHYLLUM NODOSUM; CAPILLARY ELECTROPHORESIS; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; COMPLEX FORMATION; GEL ELECTROPHORESIS; HUMAN; INHIBITION KINETICS; MOLECULAR WEIGHT; PRIORITY JOURNAL; SEAWEED; BROWN ALGA; CHEMISTRY; COMPLEMENT ACTIVATION; IMMUNOLOGY; METABOLISM;

ALGAE; ASCOPHYLLUM NODOSUM;

ALGAE, BROWN; ANTI-INFLAMMATORY AGENTS; COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1Q; COMPLEMENT C1R; COMPLEMENT C1S; COMPLEMENT C4; HUMANS; LYSINE; MULTIENZYME COMPLEXES; POLYSACCHARIDES; SULFURIC ACID ESTERS;

EID: 0344475080     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9639(03)00230-9     Document Type: Article

References (53)

1. Angstwurm K., Weber J.R., Segert A., Bürger W., Weih M., Freyer D., Einhäupl K.M., Dirnagl U. Fucoidin, a polysaccharide inhibiting leukocyte rolling, attenuates inflammatory responses in experimental pneumococcal meningitis in rats. Neurosci. Lett. 191:1995;1-4.
2. Dell'Antonio G., Quattrini A., Dal-Cin E., Fugenzi A., Ferrero M.E. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum. 46:2002;3378-3385.
3. Speth C., Würzner R., Stoiber H., Dierich M. The complement system: pathophysiology and clinical relevance. Wien. Klin. Wochenschr. 111:1999;378-391.
4. Tedesco F., Fischetti F., Pausa M., Dobrina A., Sim R., Daha M. Complement-endothelial cell interactions: pathophysiological implications. Mol. Immunol. 36:1999;261-268.
5. Winkler M. Ancient proteins and futuristic surgery: the role of complement in discordant xenograft rejection. Transplant. P.33:2001;3862-3864.
6. Dalmasso A.P., Benson B.A., Schroeder A.A., Abrahamsen M.S. Biochemical basis for induction of resistance to human complement in porcine endothelial cells by a-Gal ligation. Transplant. P.32:2000;974.
7. Mollnes T., Fiane A. Xenotransplantation: how to overcome the complement obstacle? Mol. Immunol. 36:1999;269-276.
8. Mikata S., Miyagawa S., Kamiike W., Ito T., Matsuda H., Iwata K., Nagasawa S., Seya T., Shirakura R. New approach to prevent complement activation on xenografts: effects of a surface-bound form of human C4b binding protein. Transplant. P.30:1998;65-66.
9. McGeer P., McGeer E. Inflammation, autotoxicity and Alzheimer's disease. Neurobiol. Aging. 22:2001;799-809.
10. Lue L.-F., Rydel R., Brigham E., Yang L.-B., Hampel H., Murphy G., Brachova L., Yan S.-D., Walker D., Shen Y., Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia. 35:2001;72-79.
11. Bergamaschini L., Donarini C., Gobbo G., Parnetti L., Gallai V. Activation of complement and contact system in Alzheimer's disease. Mech. Ageing Dev. 122:2001;1971-1983.
12. Chevolot L., Foucault A., Chaubet F., Kervarec N., Sinquin C., Fisher A.-M., Boisson-Vidal C. Further data on the structure of brown seaweed fucans: relationships with anticoagulant activity. Carbohydr. Res. 319:1999;154-165.
13. Daniel R., Berteau O., Jozefonvicz J., Goasdoue N. Degradation of algal (Ascophyllum nodosum) fucoidan by an enzymatic activity contained in digestive glands of the marine mollusc Pecten maximus. Carbohydr. Res. 322:1999;291-297.
14. Daniel R., Berteau O., Chevolot L., Varenne A., Gareil P., Goasdoue N. Regioselective desulfation of sulfated L-fucopyranoside by a new sulfoesterase from the marine mollusk Pecten maximus. Eur. J. Biochem. 268:2001;5617-5626.
15. Chevolot L., Mulloy B., Ratiskol J., Foucault A., Colliec-Jouault S. A dissacharide repeat unit is the major structure in fucoidan from two species of brown algae. Carbohydr. Res. 330:2001;529-535.
16. Lambris J., Reid K., Volanakis J. The evolution, structure, biology and pathophysiology of complement. Immunol. Today. 20:1999;207-211.
17. Lesavre P., Hugli T., Esser A., Müller-Eberhard H. The alternative pathway C3/C5 convertase: chemical basis of Factor B activation. J. Immunol. 123:1979;529-534.
18. Rawal N., Pangburn M. Structure/function of C5 convertase of complement. Int. Immunopharmacol. 1:2001;415-422.
19. Kazatchkine M., Hauptmann G., Nydegger U. Dosages hémolytiques des composants du Complément. Editions Inserm Techniques du Complément, Techniques en Immunologie. 1985;15-44 Société française d'Immunologie, Paris.
20. Nardella A., Chaubet F., Boisson-Vidal C., Blondin C., Durand P., Jozefonvicz J. Anticoagulant low molecular weight fucans produced by radical process and ion exchange chromatography of high molecular weight fucans extracted from the brown seaweed Ascophyllum nodosum. Carbohydr. Res. 289:1996;201-208.
21. Mulloy B., Gee C., Wheeler S.F., Wait R., Gray E., Barrowcliffe T.W. Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. Thromb. Haemost. 77:1997;668-674.
22. Blondin C., Chaubet F., Nardella A., Sinquin C., Jozefonvicz J. Relationships between chemical characteristics and anticomplementary activity of fucans. Biomaterials. 17:1996;597-603.
23. n-IgG complexes. Blood. 88:1996;184-193.
24. Krumdieck R., Höök M., Rosenberg L., Volanakis J. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J. Immunol. 149:1992;3695-3701.
25. Gorsky J., Hugli T., Müller-Eberhart H. C4a: the third anaphylatoxin of the human complement system. J. Immunol. 76:1979;5299-5302.
26. Wuillemin W., te Velthuis H., Lubbers Y., de Ruig C., Eldering E., Hack E. Potentiation of C1 inhibitor by glycosaminoglycans. J. Immunol. 159:1997;1953-1960.
27. Roos A., Nauta A., Broers D., Faber-Krol M., Ttouw L., Drifjfhout J.W., Daha M. Specific inhibition of the classical complement pathway by C1q-binding peptides. J. Immunol. 167:2001;7052-7059.
28. Kirschfink M., Blase L., Engelmann S., Schwartz-Albeiz R. Secreted chondroitin sulfate proteoglycan of the human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J. Immunol. 158:1997;1324-1331.
29. Varenne A., Gareil P., Colliec-Jouault S., Daniel R. Capillary electrophoresis determination of the binding affinity of bioactive sulfated polysaccharides to proteins. Study of the binding properties of fucoidans to antithrombin. Anal. Biochem. 315:2003;152-159.
30. Snyder S., Sobocinki P.Z. An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal. Biochem. 64:1975;284-288.
31. Lee M.K., Lander A.D. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoresis approach. Proc. Natl. Acad. Sci. U. S. A. 88:1991;2768-2772.
32. Volpi N., Sandri I., Venturelli T. Activity of chondroitin ABC lyase and hyalurodinase on free-radical degraded chondoitin. Carbohydr. Res. 279:1995;193-200.
33. Fryer J., Leventhal J., Pao W., Stadler C., Jones M., Walsh T., Zhong R., Zhang Z., Wang H., Goodman D., Kurek M., D'Apice A., Blondin B., Ivancic D., Buckingham F., Kaufman D., Abecassis M., Stuart F., Anderson B. Synthetic peptides which inhibits the interaction between C1q and immunoglobulin and prolong xenograft survival. Transplantation. 70:2000;828-836.
34. Jiang H., Siegel J.N., Gewurz H. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J. Immunol. 146:1991;2324-2330.
35. Silvestri L., Baker J., Roden L., Stroud R. The C1q inhibitor in serum is a chondroitin 4-sulfate proteoglycan. J. Biol. Chem. 256:1981;7383-7387.
36. Narayanan C.S., Chittampalli S., Krakow J.S. Effect of lysine modification on the activity of the s subunit of Escherichia coli RNA polymerase. Biochemistry. 21:1982;6103-6111.
37. Blondin C., Fisher E., Boisson-Vidal C., Kazatchkine M.D., Jozefonvicz J. Inhibition of complement activation by natural sulphated polysaccharides (fucans) from brown seaweed. Mol. Immunol. 31:1994;247-253.
38. Sahu A., Pangburn M.K. Identification of multiple sites of interaction between heparin and the complement system. Mol. Immunol. 30:1993;679-684.
39. Almeda S., Rosenberg R., Bing D. The binding properties of human complement component C1q. J. Biol. Chem. 258:1982;785-791.
40. Jiang H., Robey F.A., Gewurz H. Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 of the human C1q A chain. J. Exp. Med. 175:1992;1373-1379.
41. Jiang H., Cooper B., Robey F.A., Gewurz H. DNA binds and activates complement via residues 14-26 of the human C1q A chain. J. Biol. Chem. 267:1992;25597-25601.
42. Jiang H., Burdick D., Glab C., Cotman C., Tenner A. B-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:1994;5050-5059.
43. Maeda S., Takamaru Y., Fukatsu J., Nagasawa S. Identification of a surface structure in the fourth component of human complement, C4, which becomes hidden upon activation by C1s. Biochem. J. 289:1993;503-508.
44. Law A., Dodds A. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 6:1997;263-274.
45. Sahu A., Lambris J. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology. 49:2000;133-148.
46. Marsh J., Pratt J., Sacks S. Targeting the complement system. Curr. Opin. Nephrol. Hypertens. 8:1999;557-562.
47. Meri S., Jarva H. Complement regulation. Vox Sang. 74:1998;291-302.
48. Makrides S. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50:1998;59-87.
49. Calabrese G., Recondo M., Fernandez de Recondo M., Recondo E. The first component of the human complement system recognizes the active fraction of heparin. Cell. Mol. Biol. 43:1997;237-242.
50. Maillet F., Petitou M., Choay J., Kazatchkine M.D. Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol. Immunol. 25:1988;917-923.
51. Hugli T.E. Structure and function of the anaphylatoxins. Springer Semin. Immunol. 7:1984;193-219.
52. Farkas I., Baranyi L., Takahashi M., Fukuda A., Liposits Z., Yamamoto T., Okada H. A neuronal C5a receptor and an associated apoptotic signal transduction pathway. J. Physiol. 507:1998;679-687.
53. Reid K., Colomb M., Petry F., Loos M. Complement component C1 and the collectins-first-line defense molecules in innate and acquired immunity. Trends Immunol. 23:2002;115-117.